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Abstract
Purpose To compose a battery of instruments that pro-
vides a detailed assessment of health status (HS) in COPD
but that is applicable and clinically meaningful in routine
care.
Methods In a previous study, we developed the Nijmegen
Integral Assessment Framework (NIAF) that organizes
existing tests and instruments by the sub-domains of HS
they measure. Based on clinical and statistical criteria
(correlation coefﬁcients and Cronbach alpha’s) we selected
for each sub-domain instruments from the NIAF. A COPD-
study group was used to determine c-scores, and two
control groups were used to determine the score ranges
indicating normal functioning versus clinically relevant
problems for each sub-domain. Existing questionnaire
completion software (TestOrganiser) was adapted to
enhance clinical applicability.
Results The NCSI measures eleven sub-domains of
physiological functioning, symptoms, functional impair-
ment, and quality of life. The TestOrganiser automatically
processes the data and produces the graphical PatientPro-
ﬁleChart, which helps to easily interpret results. This
envisages the problem areas and discrepancies between the
different sub-domains.
Conclusion The NCSI provides a valid and detailed pic-
ture of a patient’s HS within 15–25 min. In combination
with the PatientProﬁleChart, the NCSI can be used per-
fectly in routine care as screening instrument and as a guide
in patient-tailored treatment.
Keywords COPD  Health status  Patient-tailored
treatment  Quality of life  Screening instrument
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Introduction
Chronic obstructive pulmonary disease (COPD) is a
chronic, progressive, and incapacitating disease. Tradi-
tionally, treatment of COPD is focused on improving or
maintaining physiological functioning of the patient.
However, in the past decade, it is recognized that besides
physiological functioning also symptoms, functional limi-
tations and quality of life (QoL) are important domains of
health status (HS) in these patients [1, 2].
Studies have shown that symptoms, functional impair-
ment, and QoL are relatively unrelated to physiological
functioning [3–5]. In a previous study, we also have shown
that these four main domains of HS were shown to be
subdivided into 15 relatively unrelated sub-domains [6].
An individual patient may experience clinically relevant
problems in some of these sub-domains, but not in other
sub-domains. As a consequence, to tailor treatment to the
speciﬁc needs of the individual patient, it is necessary to
obtain an integral and detailed picture of HS of all sub-
domains.
In routine care, physiological functioning is measured
by lung function tests. Although, many generic and dis-
ease-speciﬁc questionnaires are available to measure
symptoms, functional impairment and QoL [3, 7], these
three main domains commonly are not measured in routine
care. A major reason for this is that current questionnaires
are not suitable for application in routine care. This has
several causes. First, questionnaires commonly consist of
many items and are therefore time-consuming. Second, the
scoring of questionnaires is often complex and has to be
done by hand, which is also time-consuming. Third, the
clinical meaning of a particular score is often unclear due
to the lack of adequate normative data. Normality cannot
be deﬁned by absence of, e.g., symptoms. As patients with
COPD are often elderly, the presence of an elevated score
can also be the result of normal aging instead of being the
result of having COPD. Moreover, symptoms such as
fatigue or shortness of breath may be experienced by
healthy persons as well. Hence, it is important to know
whether a score represents normal functioning or clinically
relevant problems. Fourth, in a previous study, we found
that existing questionnaires measure only one to three
aspects of HS [6]. In addition, we have shown that there is
considerable overlap between questionnaires with respect
to the speciﬁc sub-domains they measure. This implicates
that, for an integral and detailed assessment of HS, a
combination of several instruments is required in that
overlap should be avoided.
Consequently, the following criteria must be fulﬁlled to
permit adequate assessment of HS suitable and useful in
routine care: (1) a broad spectrum of aspects of HS has to
be measured to obtain a comprehensive and detailed pic-
ture; (2) instruments should be as short as possible, but still
have enough items to warrant adequate reliability; (3)
overlap should be avoided; (4) scoring must be simple and
results should be available immediately, preferably this
should be automated; and (5) results should be easy to
interpret and should indicate if a particular score indicates
normal functioning or clinically relevant problems. Such an
instrument would provide the clinician with a tool to
identify patients who need additional treatment and pro-
vides a detailed picture on the type and severity of prob-
lems in HS of an individual patient, and thereby can help
the clinician in patient-tailored treatment. In addition, it
also could be used for outcome assessment, as part of an
intervention, and for research studies.
The aim of the present study was to compose a battery
of existing questionnaires that fulﬁlls all above-mentioned
criteria for clinical applicability in a routine care outpatient
setting. In this process we used the Nijmegen Integral
Assessment Framework (NIAF) [6] as a guide for the
selection of instruments. The NIAF is an evidence-based
framework that organizes tests and questionnaires by
indicating which sub-domains of HS actually are measured
by speciﬁc (sub-)scales of various existing instruments.
Data of matched control groups were used to determine
cut-offs for each instrument to indicate normal functioning
versus clinically relevant problems. In addition, existing
software for computerized questionnaire completion was
adapted speciﬁcally to facilitate clinical applicability of the
test battery and easy interpretation of results.
Method
Subjects
COPD-study group
For the selection of instruments of the Nijmegen Clinical
Screening Instrument (NCSI) we used the data from a
sample of COPD patients that are representative for patients
with stable COPD (GOLD II and III), with no primary
co-morbidity, in routine care at outpatient clinics. This
COPD-study group was recruited from three different
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123pulmonary outpatient clinics in the Netherlands: University
Lungcenter Dekkerswald of the Radboud University Nij-
megen Medical Center, Maas Hospital Boxmeer and Rijn-
state Hospital Arnhem. Inclusion criteria were diagnosis of
GOLD II/III (FEV1% predicted between 30 and 80%),
FEV1/FVC\70%, and reversibility of obstruction\12%.
Exclusion criteria were primary co-morbidity that may
dominate HS, recent participation in a rehabilitation pro-
gram (within previous 6 months), inability to speak or read
Dutch, acute exacerbation of COPD, and inability to com-
pletely adhere to the research protocol. Screening the
patient charts resulted into 361 eligible patients. A pulmo-
nologist asked these patients for permission to be called by
the investigator, and 316 (88%) agreed to be called for
further information. One hundred sixty-eight patients (47%)
participated in this study (see Table 1 for patient charac-
teristics). Reasons for non-participation were diverse; pre-
dominantly being too busy, refusing cycle-ergometry, and
travel problems. Patients gave informed consent and the
local Ethics Committee approved this study.
Control samples
To determine the score range of the selected instruments
that represents clinically relevant problems, we recruited
patients with COPD included in a clinical multi-disciplinary
pulmonary rehabilitation program at the University Lung-
center Dekkerswald of the Radboud University Nijmegen
Medical Center. A key requirement for inclusion in this
program is that patients have to experience clinically rele-
vant problems in multiple areas of HS. The decision on this
requirement was based on a 3-days intake procedure, in
which elaborate assessments, physiological tests, and clin-
ical interviews by seven disciplines (pulmonologist, psy-
chotherapist, physiotherapist, nurse, dietitian, psychomotor
therapist, social worker) took place. The results of these
assessments and interviews are evaluated in a multi-disci-
plinary discussion. Inclusion criteria were diagnosis of
COPD [8] and clinically relevant problems in multiple areas
of HS. Exclusion criteria: mild or isolated problems in HS
and inability to speak or read Dutch. Subjects were matched
to the COPD-study group by age and sex. See Table 1 for a
description of this sample.
To determine the score range of instruments indicating
normal functioning, we recruited healthy controls by an
advertisement in a regional newspaper. Exclusion criteria
were having asthma or COPD, being under regular treat-
ment of any specialist and/or inability to speak or read
Dutch. The subjects were screened for absence of chronic
illnesses by one of the investigators (LD). Subsequently,
lung function testing was performed. Based on all assess-
ments a pulmonologist (JM) decided whether a person
could be included or not. Subjects were matched on age
and sex to the COPD-study group. See Table 1 for a
description of this sample.
Measurements
In a previous study, we deﬁned four domains of HS;
physiological functioning, symptoms, functional impair-
ment, and QoL [6]. These four main domains of HS were
found to be subdivided into 15 relatively unique sub-
domains, which together constitute the NIAF for COPD.
See Fig. 1 for a general description of the development and
validation of the NIAF. For a detailed description on the
development and validation of the NIAF see elsewhere [6].
In a recent, yet, unpublished study, we found fatigue to
be an important symptom in COPD that is relatively
independent to the other sub-domains. For that reason,
fatigue was included in the framework as a separate sub-
domain of the main domain symptoms. Table 2 shows the
instruments that measure the sub-domains of HS.
Questionnaire completion was performed by the Test-
Organiser, which is a computerized questionnaire system
developed by the Department of Medical Psychology and
the Department of Instrumental Services of the Radboud
University Nijmegen Medical Centre [6]. Questionnaires
are presented in the same layout as paper-and-pencil
Table 1 Patient characteristics expressed in number (%) unless sta-
ted otherwise of the COPD outpatient study group (OP), patients
included in pulmonary rehabilitation (PR), and Healthy controls (HC)
OP PR HC
N 168 131 69
Male 131 (78%) 89 (67.9%) 48 (69.6%)
Age [mean (SD)] 64.5 (9.1) 62.1 (7.3) 62.4 (7.8)
Range 43–80 46–78 41–76
FEV1% pred [mean (SD)] 51.6 (13.6) 35.0 (13.0) 111.7 (14.8)
GOLD
Stage 1 0 (0%) 0 (0%) 0 (0%)
Stage 2 88 (52.4%) 18 (13.7%) 0 (0%)
Stage 3 80 (47.6%) 63 (48.1%) 0 (0%)
Stage 4 0 (0%) 50 (38.2%) 0 (0%)
BMI [mean (SD)] 25.6 (4.1) 24.4 (4.2) 26.4 (3.9)
Education
Low 85 (52.1%) 68 (51.9%) 20 (29.0%)
Middle 48 (29.4%) 38 (29.0%) 18 (26.1%)
High 30 (18.4%) 25 (19.1%) 21 (44.8%)
Personal situation
Partner 137 (84.0%) 105 (80.1%) 52 (75.4%)
Divorced 7 (4.3%) 6 (4.6%) 8 (11.6%)
Widowhood 11 (6.7%) 9 (6.9%) 3 (4.3%)
Single 8 (4.9%) 11 (8.4%) 6 (8.7%)
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123versions, items cannot be skipped, and both scoring and
data storage are automated.
Construction of the Nijmegen Clinical Screening
Instrument
The NIAF organizes existing instruments by the sub-
domains of HS they measure. Each sub-domain was mea-
sured by several tests or instruments or subscales of
instruments (Table 2), and can be used interchangeably.
Based on the following criteria we selected for each sub-
domain one or two instruments for inclusion of the NCSI.
A. Preliminary selection of instruments
1. The scores on selected instruments should show a
correlation of[0.70 with the original NIAF-STS
[9].
2. The selected instruments must be completed in as
little time as possible (preferably \30 min), in
other words a minimum number of items but
should show good reliability (Cronbach’s alpha[
0.70).
3. Although all instruments included in the NIAF are
clinically relevant, in the selection process of
instruments we also considered which instrument
was most clinically relevant. These decisions
were based on clinical experience of the pulmo-
nologists (JM, YH, RD) and the clinical psychol-
ogist (JV).
B. Statistical analysis on the preliminary selection
1. For each sub-domain of HS, selected instruments
were combined into a sub-domain total score
(NCSI-STS) by adding scores of respective
instruments. Spearman correlation coefﬁcients
between the original NIAF-STS and the new
NCSI-STS were calculated and had to be higher
than 0.70, which is considered a criterion for
instruments to measure the same concept [9, 10].
2. To test possible overlap between the sub-domains
the inter-correlations between all NCSI-STS were
calculated by spearman coefﬁcients, and should
be lower than 0.70.
3. The Cronbach’s alpha reliability coefﬁcients
(internal consistency) of each NCSI-STS should
be at least be moderate ([0.50) and preferably
[0.70 [9].
Construction of normative data
For each subscale, the total score range of the COPD-study
group was transformed to C-scores. C-scores are similar to
percentile scores, but differentiate more in the extremes of
the score range and correct for skewed distributions. The
score range is 1–11, and the scores refer to the following
percentiles, respectively: 1.2–4.0–10.6–22.7–40.1–59.9–
77.3–89.4–96.0–98.8–100%. For each instrument the score
belonging to the 80th percentile of the Healthy Controls
was used as the maximal score of normal functioning
(green colored score range), and the score belonging to the
20th percentile of the pulmonary rehabilitation patients was
used as the minimum score representing clinically relevant
problems (red colored score range). The area between
green and red has been labeled ‘elevated’(yellow).
New features of the TestOrganiser
The TestOrganiser was originally developed for the pur-
pose of data collection in research. In the past 3 years, the
TestOrganiser has been implemented in our inpatient and
outpatient clinic to develop and test clinical applicability
and patient acceptability in routine care. The software of
the TestOrganiser was revised in several aspects and new
features were developed. These revisions particularly
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123concerned automated data processing. The most important
new feature is the graphical presentation of results on the
level of an individual patient (the PatientProﬁleChart) to
facilitate ease of interpretation of results for clinical
purposes.
Results
No signiﬁcant differences were found between the COPD-
study group and the two control groups with respect to age
and sex (Table 1).
Construction of the Nijmegen Clinical Screening
Instrument
A. Preliminary selection of instruments
The preliminary selection of instruments for the NCSI is
shown in Table 2. The instruments in bold were selected
for the NCSI. The sub-domains exercise capacity, gas
exchange and muscle strength require cycle-ergometry
testing and muscle strength tests are too time-consuming
for use in a routine care outpatient setting and, therefore,
were excluded. The sub-domains expected dyspnea (main
domain symptoms) and actual physical activity (main
domain functional impairment) were excluded because
these tests also are too time-consuming: the PARS-
expected dyspnea consist of 20 items, and the accelerom-
eter has to be worn for 12 days.
With respect to the sub-domain dyspnea emotions (main
domain symptoms) we included dyspnea-related anxiety
instead of dyspnea-related mood despite the higher corre-
lation of the latter, because dyspnea-related anxiety is far
more common in COPD than dyspnea-related depressed
mood. With respect to the sub-domain subjective symp-
toms (main domain symptoms), we included the PARS-D
global dyspnea burden (1 item) instead of the PARS-D
activity (14 items) for reasons of brevity.
B. Statistical analysis on the preliminary selection
The correlations between the sub-domain total scores of
the NIAF (NIAF-STS) and the NCSI (NCSI-STS) all
exceeded 0.70, which indicates that the NCSI-STS are
conceptually similar to the NIAF-STS (Table 3). In addi-
tion, all Cronbach’s alphas of the NCSI-STS were[0.70,
except those of general QoL (0.61) and satisfaction rela-
tions (0.64) (Table 3). In general, there was none or at best
moderate overlap between the sub-domains of the NCSI-
STS as expressed by non-signiﬁcant to at best moderate
inter-correlations (Table 4).
Additional items were added to measure smoking-status
(yes/no) and willingness to quit smoking (yes/no).
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123Construction of normative data
Characteristics of the sub-domains included in the NCSI
for all study groups are presented in Table 5. As expected,
in healthy controls there was a strong ﬂoor effect on dis-
ease-related domains: symptoms (except fatigue) and
functional impairment. In general, there were no evident
problems related to ﬂoor and ceiling effects in both COPD
groups. As expected, the pulmonary rehabilitation control
group showed the highest scores on all sub-domains and
healthy controls the lowest.
New features of the TestOrganiser
To enable patients with no prior computer experience to
complete the questionnaires easily, a simple response board
was developed with a minimum of (large) buttons. A net-
work function was integrated that enables immediate
access to the results after test completion on every com-
puter in the hospital. The most important new feature is the
automatic production of graphical representations of the
results: the PatientProﬁleChart (see Fig. 2). The Patient-
ProﬁleChart (PPC) provides a graphical presentation of the
scores of an individual patient. Each column represents a
speciﬁc instrument within a sub-domain. All score ranges
are based on the reference sample (COPD-study group) and
are expressed as C-scores. The x represents the score of the
individual patient. First, the x indicates how a patient
scores in relation to the general COPD population. For
example, the patient in Fig. 2 had a raw score on Depres-
sion of 3 which falls in the 7th C-score of the COPD ref-
erence sample. This means that 77, 3% of the reference
sample had a lower score. Second, the score range of each
instrument is divided into colored ranges that allow abso-
lute interpretations. The green score range indicates ‘nor-
mal functioning’, the yellow score range indicates ‘mild
problems’, and the red score range indicates ‘clinically
relevant problems’. The patient in Fig. 2 scored in the
yellow area (‘mild problems’). Thus, although this patient a
higher score than 77% of the COPD reference sample (7th
C-score), still this score did not indicate clinically relevant
problems.
Discussion
In the present study, we developed the NCSI that is short
enough to be completed in routine care, but stills provides
much detail on a patient’s HS. In addition, the TestOrgan-
iser was adapted to further improve clinical applicability of
the NCSI in routine care. To facilitate interpretation of a
patient’s scores, we developed the PatientProﬁleChart that
presents results graphically. In addition, we determined cut-
offs based on reference groups indicating whether a
Table 3 Correlations between the sub-domains measured by the NCSI-sub-domain total scores (NCSI-STS) versus the NIAF-sub-domain total
scores (NIAF-STS) (P\0.01), and Cronbach’s alpha reliability coefﬁcients of all NCSI-STS
Domain Sub-domain Subscale/test Correlation NCSI-STS
versus NIAF-STS
Number
of items
Cronbach’s
alpha
Physiological
functioning
Static lung volumes TLC % predicted 0.99 –
RV % predicted
Airﬂow Post-bronchodilator FEV1% predicted -0.91 –
Body composition BMI -0.95 –
Symptoms Subjective symptoms PARS-D global dyspnea activity 0.93 2 0.85
PARS-D global dyspnea burden
Dyspnea emotions DEQ frustration 0.96 6 0.82
DEQ anxiety
Fatigue CIS fatigue 1.00 8 0.83
Functional impairment Behavioural
impairment
SIP home management 0.91 22 0.72
SIP ambulation
Subjective impairment QoL-RiQ general activities 0.90 4 0.88
Quality of life General QoL Satisfaction with life scale 0.94 12 0.61
BDI primary care
HRQoL Satisfaction physical 1.00 2 0.71
Satisfaction future
Satisfaction relations Satisfaction spouse 1.00 2 0.64
Satisfaction social relations
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123particular score indicates normal functioning or clinically
relevant problems.
Guidelines for treatment of COPD emphasize the
importance of maintaining and optimizing HS [8, 11, 12],
and describe for every COPD severity stage (based on the
degree of airway obstruction; I–IV) what type of treatment
is indicated. Pulmonary rehabilitation, for example, is
indicated for GOLD stages III–IV. However, HS consists
of four main domains: physiological functioning, symp-
toms, functional impairment, and quality of life [1, 2, 6,
13], divided into at least unique 15 sub-domains [6]. Given
the ﬁndings of many studies showing that FEV1 is poorly
related to symptoms, functional impairment and quality of
life [3–5, 14] it is impossible to determine the status of
other sub-domains of HS on the basis of FEV1 alone. Thus,
FEV1 gives no information on any aspect of HS other than
airway obstruction, and as such is a poor indicator for
speciﬁc interventions such as pulmonary rehabilitation.
Consequently, tailoring treatment to the needs of the
individual patient requires an integral and detailed picture
of the individual patient’s HS by measuring of all four
main domains and their many sub-domains.
Many generic and disease-speciﬁc instruments have
been developed to measure HS in COPD patients [3, 7].
However, most of these instruments are rather lengthy,
scoring is time-consuming, commonly measure only few
aspects of HS, and in many cases it is unclear whether a
score represents normal functioning or clinically relevant
problems, due to the lack of normative data. In addition, as
existing instruments measure only few aspects of HS, the
Fig. 2 The PatientProﬁleChart;
graphical representations of the
patients’ results
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123need for a detailed assessment of HS to enable patient-
tailored treatment requires the combination of multiple
instruments. However, such a battery of instruments would
diminish clinical applicability even further as this would
increase problems with regard to the length of instruments,
time-consuming scoring procedures, as well as the overlap
found between instruments [6].
The need for short questionnaires that allow measure-
ment of symptoms, functional impairment, and quality of
life in routine care has been acknowledged by other
researchers. Several instruments have been developed for
this purpose; the clinical COPD questionnaire (CCQ) [15],
the respiratory illness questionnaire—monitoring 10 (RIQ-
MON10) [16], and the EuroQOL (EQ-5D) [17]. These
instruments are short (six to ten items) and have shown
good validity and reliability. However, the CCQ measures
only three sub-domains of HS, the RIQ-MON10 measures
only two sub-domains, and the EQ-5D measures only
three sub-domains. Although, these instruments are short
and easy to score, these do not provide a detailed picture
of the patient’s HS, and lack normative data indicating
normal functioning versus clinically relevant problems.
Hence, these instruments still do not satisfy all require-
ments for clinical applicability as pointed out in the
introduction.
We did not develop a new instrument, as we did not
want to add to the abundance of instruments already
available, but we set out for a new approach that would
render existing instruments suitable for use in routine care.
We composed a battery of existing instruments with a
minimum number of items, but with a maximum of detail
of HS, a minimum of overlap between instruments, and
good reliability and validity. Although clinical consider-
ations did play a role in the selection process of instru-
ments, decisions were not based on personal preferences of
the researchers, or on how frequent a particular instrument
is used in COPD research. The selection of instruments
from the empirically validated integral assessment frame-
work of HS in COPD [6], the NIAF, was primarily guided
by statistical analyses. The NIAF contains 16 sub-domains
of HS covering the main domains physiological function-
ing, symptoms, functional impairment, and quality of life.
In addition, this framework provides additional validity
information on many existing instruments: it indicates what
sub-domain(s) of HS speciﬁc instruments measure, and it
indicates which instruments measure the same sub-domains
of HS.
Although the NCSI enables a quick (15–25 min) and
detailed assessment of HS, typical questionnaire problems
such as complex scoring procedures and the problem of
interpretability of results remained. To provide a solution
for these problems the software of the TestOrganiser was
adapted. This involved automatic scoring, a network
facility, and the development of a special response board.
After instructions, additional questions of patients pre-
dominantly were related to the content of the questionnaire
items, and rarely with regard to computer operating.
The most important new feature of the TestOrganiser is
the PatientProﬁleChart. Immediately after completion of
the NCSI, the PatientProﬁleChart is generated by the
TestOrganiser, is available on every authorized computer
in the clinic, and can immediately be discussed with the
patient. The interpretation of the PatientProﬁleChart is very
easy for the clinician, but also for the patient. A short
training for clinicians is sufﬁcient to learn how to interpret
the PatientProﬁleChart. The colored areas of the score
range of each instrument indicate whether a patient shows
normal functioning in a particular sub-domain of HS or
clinically relevant problems.
Psychometric properties of the NCSI are good. The
correlations between the NCSI-STS and the corresponding
NIAF-STS were high and well above the criterion for
conceptual similarity. Within the NCSI there was little
overlap between the NCSI-STS as expressed by non-sig-
niﬁcant to at best moderate inter-correlations. This also
indicates that each sub-domain of the NCSI represents a
unique aspect of a patient’s HS. The internal consistency of
the NCSI-sub-domain total scores in general were good,
except the general Qol and satisfaction relations.
Some methodological issues need to be addressed. First,
in the present study the test–retest reliability, and the
responsiveness-to-change of the instruments used to mea-
sure the sub-domains of HS were not tested. However,
inclusion of instruments with adequate psychometric prop-
ertieswasoneoftheselectioncriteriafortheNIAF.Formost
of the included instruments test–retest reliability and
responsiveness-to-change were found adequate in other
studies [18, 19, 21, 24]. Second, not all sub-domains of HS
are measured by the NCSI. Some sub-domains required
measurementsthataretootime-consumingforuseinroutine
care at an outpatient clinic (e.g. cycle-ergometry testing,
accelerometry).Futurestudiesareneededtoﬁndalternatives
that can be used for measuring those sub-domains in routine
care. Nevertheless, the decision on what speciﬁc measure-
ments are too time-consuming also may depend on speciﬁc
settings.Theﬁnalissuereferstotheuseofcontrolgroupsand
the need for cut-offs. Normal functioning cannot be deﬁned
by absence of symptoms or functional impairment, for
example,duetoeffectsofnormalageing.Thismeansthatthe
upper part of the score range in healthy subjects indicates
abnormal functioning. Therefore, we used the 80th percen-
tile of healthy controls as the upper limit of normal func-
tioning. Similarly, ‘clinically relevant problems’ cannot be
deﬁnedbythemerepresenceofsuchproblems.Forexample,
healthy subjects may experience fatigue or shortness of
breath as well. In addition, even patients with multiple and
910 Qual Life Res (2009) 18:901–912
123severe problems in HS (the inpatient pulmonary rehabilita-
tion controls) may not have problems in all sub-domains. So
we assumed that for each sub-domain the lower part of the
score range of the rehabilitation patients overlaps with the
score range of normal functioning or mild problems.
Therefore, we chose the 20th percentile of the pulmonary
rehabilitation patients as the cut-offs for clinically relevant
problems. Although the method we used to calculate cut-off
scores indicating normal functioning versus clinically rele-
vant problems is an accepted approach [25], to a certain
degree these cut-offs remain arbitrary. However, decisions
on,forexample,whichpatientsdoneedadditionaltreatment
versus those who do not, never depend on one single sub-
domain, but on the proﬁle on all sub-domains. Most impor-
tant criteria in this respect are the number of sub-domains
showing clinically relevant problems and discrepancies
between the severity of physiological sub-domains versus
the sub-domains measuring symptoms, functional impair-
ment, or quality of life. This may render the arbitrariness of
cut-offs less problematic. In addition, the clinical relevance
of the cut-offs (i.e. the proﬁles) were clinically tested during
3 years in different settings and proved to be quite accurate.
The NCSI can be used for several clinical purposes.
Screening and monitoring. In our centre, every year the
patient completes the NCSI during a regular visit. In this
way, problems in all four domains of HS are revealed in an
early stage.
Decision making. The proﬁle of the PatientProﬁleChart
indicates which type of intervention would be required for
this individual patient (e.g. pulmonary nurse, an outpatient
or multi-disciplinary pulmonary rehabilitation program).
As pointed out above, such decisions are based on the
proﬁle of all sub-domains. Additionally, the discussion of
the PatientProﬁleChart with patient and partner elucidates
the mechanisms underlying the problems in HS. This
provides additional information on which type of inter-
vention is best suited.
Motivational intervention. The NCSI and PatientPro-
ﬁleChart can be used as an intervention to increase the
patient’s motivation to adopt adequate health behaviors
(e.g. stop smoking, regular exercise) or to enroll in addi-
tional treatment (e.g. rehabilitation program). This is simply
done by discussing the PatientProﬁleChart with the patient
and his partner. The motivational effect is achieved by
several psychological mechanisms ‘hidden’ in this proce-
dure. The most important are ﬁrstly, results are presented
graphically, which has much greater impact than words, and
thereby powerfully increases awareness of the severity of
his problems. Secondly, the proﬁle is the resultant of
responses of the patient himself and does not reﬂect the
opinion of the clinician. This increases commitment and
avoids conﬂicting opinions. The NCSI can also be used for
outcome assessment and research purposes.
In conclusion, in this study we composed a battery of
instruments that enables the clinician to obtain a valid,
reliable, and detailed picture of a patient’s HS by mea-
suring multiple sub-domains covering all four main
domains. In combination with the TestOrganiser and the
PatientProﬁleChart, the NCSI can easily be used in routine
care as a guide in patient-tailored treatment.
Acknowledgments We are indebted to Dr. F. van den Elshout
(pulmonologist, Rijnstate Hospital, Arnhem) and Dr. R. Bunnik
(pulmonologist, Maas Hospital, Boxmeer) for their contribution in the
patient recruitment and the multi-disciplinary Taskforce Assessment
of the Department of Pulmonary Rehabilitation for their invaluable
contributions to the development of the conceptual models. The study
was supported by grants of the Dutch Asthma Foundation, Glaxo-
SmithKline, Stichting Astmabestrijding, and the Department of
Medical Psychology and the Department of Pulmonary Diseases,
Radboud University Nijmegen Medical Center.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Spilker, B., & Revicki, D. A. (1996). Taxonomy of quality of life.
In B. Spilker (Ed.), Quality of life and pharmaeconomics in
clinical trials (2nd ed., pp. 25–31). Philadelphia: Lippincott-
Raven.
2. Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables
with health-related quality of life. A conceptual model of patient
outcomes. The Journal of American Medical Association, 273,
59–65.
3. Curtis, J. R., & Patrick, D. L. (2003). The assessment of health
status among patients with COPD. Journal of European Respi-
ratory, 41(Suppl), 36s–45s.
4. Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1994). Why
quality of life measures should be used in the treatment of
patients with respiratory illness. Monaldi Archives for Chest
Disease, 49, 79–82.
5. Jones, P. W. (2001). Health status measurement in chronic
obstructive pulmonary disease. Thorax, 56, 880–887.
6. Vercoulen, J. H., Daudey, L., Molema, J., Vos, P., Peters, J., Top,
M., et al. (2008). An Integral assessment framework of health
status in chronic obstructive pulmonary disease (COPD). Inter-
national Journal of Behavioral Medicine, 15(4), 263–279.
7. Bowling, A. (2001). Health-related quality of life: Conceptual
meaning, use and measurement. In A. Bowling (Ed.), Measuring
disease: A review of disease-speciﬁc quality of life measurement
scales. (2nd ed., pp. 1–22). Buckingham, Philadelphia: Open
University Press.
8. Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A.,
Calverley, P., et al. (2007). Global strategy for the diagnosis,
management, and prevention of chronic obstructive pulmonary
disease: GOLD executive summary. American Journal of
Respiratory and Critical Care Medicine, 176(6), 532–555.
9. Terwee, C. B., Bot, S. D., de Boer, M. R., van der Windt, D. A.,
Knol, D. L., Dekker, J., et al. (2007). Quality criteria were pro-
posed for measurement properties of health status questionnaires.
Journal of Clinical Epidemiologie, 60(1), 34–42.
Qual Life Res (2009) 18:901–912 911
12310. Ogden, J. (2001). Theory and measurement: Conceptualisation,
operationalisation, and the example of health status. In A. Vinge-
rhoets (Ed.), Assessment in behavioral medicine (pp. 73–90). East
Sussex: Brunner-Routledge.
11. Celli, B. R. (1997). ATS standards for the optimal management
of chronic obstructive pulmonary disease. Respirology, 2(Suppl
1), S1–S4.
12. Siafakas, N. M., Vermeire, P., Pride, N. B., Paoletti, P., Gibson,
J., Howard, P., et al. (1995). Optimal assessment and manage-
ment of chronic obstructive pulmonary disease (COPD). The
European Respiratory Society Task Force. European Respiratory
Journal, 8, 1398–1420.
13. Taillefer, M., Dupuis, G., Roberge, M., & Le May, S. (2003).
Health-related quality of life models: Systematic review of the
literature. Social Indicators Research, 64, 293–323.
14. Verhage, T. L., Heijdra, Y. F., Molema, J., Daudey, L.,
Dekhuijzen, P. N. R., & Vercoulen, J. H. (2009). Adequate
patient characterization in COPD: Reasons to go beyond GOLD
classiﬁcation. Open Respiratory Medicine Journal, 3, 1–9.
15. Van Der Molen, T., Willemse, B. W., Schokker, S., Ten Hacken,
N. H., Postma, D. S., & Juniper, E. F. (2003). Development,
validity and responsiveness of the clinical COPD questionnaire.
Health and Quality of Life Outcomes, 1, 13.
16. Jacobs, J. E., Maille, A. R., Akkermans, R. P., van Weel, C., &
Grol, R. P. T. M. (2004). Assessing the quality of life of adults
with chronic respiratory diseases in routine primary care: Con-
struction and ﬁrst validation of the 10-item respiratory illness
questionnaire-monitoring 10 (RIQ-MON10). Quality of Life
Research, 13, 1117–1127.
17. The EuroQol Group. (1990). EuroQol-a new facility for the
measurement of health-related quality of life. Health Policy, 16,
199–208.
18. van Stel, H. F., Maille, A. R., Colland, V. T., & Everaerd, W.
(2003). Interpretation of change and longitudinal validity of the
quality of life for respiratory illness questionnaire (QoLRIQ) in
inpatient pulmonary rehabilitation. Quality of Life Research, 12,
133–145.
19. Wiebe, J. S., & Penley, J. A. (2005). A psychometric comparison
of the beck depression inventory-II in English and Spanish.
Psychological Assessment, 17, 481–485.
20. Maille ´, A. R., Koning, C. J., Zwinderman, A. H., Willems, L. N.,
Dijkman, J. H., & Kaptein, A. A. (1997). The development of the
‘quality-of-life for respiratory illness questionnaire (QOL-RIQ)’:
A disease-speciﬁc quality-of-life questionnaire for patients with
mild to moderate chronic non-speciﬁc lung disease. Respiratory
Medicine, 91, 297–309.
21. Vercoulen, J. H. M. M., Swanink, C. M. A., Galama, J. M. D.,
Fennis, J. F. M., van der Meer, J. W. M., & Bleijenberg, G.
(1994). Dimensional assessment in chronic fatigue syndrome.
Journal of Psychosomatic Research, 38, 383–392.
22. Vercoulen, J. H. M. M., Bazelmans, E., Swanink, C. M. A.,
Fennis, J. F. M., Galama, J. M. D., Jongen, P. J. H., et al. (1997).
Physical activity in chronic fatigue syndrome: Assessment and its
role in fatigue. Journal of Psychiatric Research, 31, 661–673.
23. Bergner, M., Bobbitt, R. A., Carter, W. B., & Gilson, B. S.
(1981). The sickness impact proﬁle: Development and ﬁnal
revision of a health status measure. Medical Care, 19, 787–805.
24. Jacobs, H. M., Luttik, A., Touw-Otten, F. W. M. M., & De
Melker, R. A. (1990). De ‘sickness impact proﬁle’; Resultaten
van een valideringsonderzoek van de Nederlandse versie.
Nederlands Tijdschrift voor Geneeskunde, 134, 1950–1954.
25. Beck, A. T., Guth, D., Steer, R. A., & Ball, R. (1997). Screening
for major depression disorders in medical inpatients with the beck
depression inventory for primary care. Behaviour Research and
Therapy, 35, 785–791.
26. Diener, E., Emmons, R. A., Larsen, R. J., & Grifﬁn, S. (1985).
The satisfaction with life scale. Journal of Personality Assess-
ment, 49, 71–75.
27. Arrindell, W. A., & Ettema, J. H. M. (1986). SCL-90: Handle-
iding bij een multidimensionele psychopathologie-indicator.
Lisse: Swets & Zeitlinger.
912 Qual Life Res (2009) 18:901–912
123